SlideShare a Scribd company logo
By Linda Self
 Regulation of water excretion
 Regulation of electrolyte function
 Regulation of acid-base balance—retain
HCO3- and excrete acid in urine
 Regulation of blood pressure--RAAS
 Regulation of RBCs
 Vitamin D synthesis
 Secretion of prostaglandin E and prostacyclin
which cause vasodilation, important in
maintaining renal blood flow
 Excretion of waste products-body’s main
excretory organ. Urea, creatinine, phosphates,
uric acid and sulfates. Drug metabolites.
Stimuli for Renin Excretion
Angiotensinogen in liver
Renin release
Angiotensin I
Converting enzyme in lungs
Angiotensin II
Renal autoregulation
Increased BP, increased circulating volume
 Renin—raises BP
 Bradykinins—increase blood flow and vascular
permeability
 Erythropoietin
 ADH
 Aldosterone—promotes sodium reabsorption
and potassium excretion
 Natriuretic hormones—released from the
cardiac atria and brain.
1. Hypertension
2. Diabetes mellitus
3. Immobilization
4. Parkinson’s disease
5. SLE
6. Gout
7. Sickle cell anemia, multiple myeloma
8. BPH
9. Pregnancy
10. SCI
 GFR decreases following 40 years with a yearly
decline of about 1 mL/min
 Renal reserve declines
 Multiple medications can result in toxic
metabolites
 Diminished osmotic stimulation of thirst
 Incomplete emptying of bladder
 Urinary incontinence
 Sp. Gravity—1.005-1.020
 Microscopic examination for protein, RBCs,
ketones, glycosuria, presence of bacteria,
general appearance and odor
 Leukocyte esterase—enzyme found in WBCs
 Nitrites –bacteria convert nitrates to nitrites
 Osmolality—accurate measurement of the
kidney’s ability to concentrate urine. Normal
range is 500-1200 mOsm/kg.
 Culture important in ‘Id’ing pathogen
 Albuminuria—albumin in urine not
measurable by dipstick
 Normal values in freshly voided sample should
range between 2.0-20 for men and 2.8-28 for
women. Higher levels indicate
microalbuminuria.
 Can also be determined by 24h specimen
 Urine osmolality—indication of concentrating
ability, changes seen early in disease processes
 Creatinine clearance—tests clearance of
creatinine in one min. Reflects GFR.
 Serum creatinine—measures effectiveness of
renal function. 0.6 to 1.2 mg/dL
 Urea nitrogen—also indicator of renal function.
7-18 mg/dL. Measures renal excretion of urea
nitirogen, a byproduct of protein metabolism.
Is not always elevated with kidney disease. Not
best indicator of renal function.
 Liver must function properly to produce urea
nitrogen. BUN levels indicate the extent of
renal clearance of this nitrogenous waste
product.
 May see elevation of BUN with bleeding into
tissues or from rapid cell destruction from
infection/steroids
 Ratio of BUN to creatinine distinguishes
between renal and non-renal factors causing
elevations
 Dehydration can affect the BUN
 When blood volume is down, or BP is low,
BUN level rises more rapidly than creatinine
level.
 Volume of fluid filtered from renal glomerular
capillaries into Bowman’s capsule per unit of
time
 Generally expressed in ml/minute
 Normal GFR generally is 125mL/minute
 Cockcraft-Gault formula
 Modification of Diet in Renal Disease Study
Group formula (MDRD)
 Schwartz formula
 Starling equation
 No common pathologic condition, other than
renal disease, increases the serum creatinine
level
 Serum creatinine does not increase until at least
50% of renal function is lost
 Is a calculated measure of glomerular filtration
rate. Is best indicator of overall kidney
function.
 Based on 24 hour urine collection
 Midway will obtain serum creatinine. Serum
creatinine levels vary with age, gender and
body muscle mass
 Calculate: (Volume of urine X urine creatinine)
Divided by serume creatinine
 KUB
 Ultrasonography
 CT
 MRI
 Nuclear scans
 IV urography—IVP. NPO before. Bowel prep.
Nephrotoxic agent. Metformin.
 VCUG
 Cystoscopy
 Ureteral brush biopsy
 Kidney biopsy
 Urodynamic tests—cystometrogram. Measures
detrusor muscle function.
 Antigen-antibody complexes form in blood and
become trapped in glomerular capillaries
 Induce an inflammatory response
 Manifested by proteinuria, hematuria,
decreased GFR and alteration in excretion of
sodium
 Acute and chronic glomerulonephritis
 Nephrotic syndrome
Antigen (group A strep)
Antigen-antibody product
Deposition of antigen-antibody complex in glomerulus
Increased production of epithelial cells lining the glomerulus
Leukocyte infultration of the glomerulus
Thickening of the glomerular filtration membrane
Scarring and loss of glomerular filtration membrane
Decreased GFR
 Staph, klebsiella, CMV, mono, hep B,
mycoplasma, group A beta-hemolytic strep
 Hematuria
 Edema
 Azotemia-accumulation of nitrogenous wastes
 Urine appearance may be cola colored
 Hypertension
 Hypoalbuminemia
 Hyperlipidemia
 Rising BUN and creatinine
 Hypertensive encephalopathy
 Heart failure
 Rapid decline in renal function can occur to
ESRD
 Treat s/s such as elevated BP
 Check GFR by 24h urine for creatinine clearance
 ANA
 Treat streptococcal infection with antibiotics,
preferably PCN
 Corticosteroids
 Immunosuppressants
 Limit dietary protein, increase CHO
 Restrict sodium
 May progress to chronic glomerulonephritis, will
treat as in CKD
 Is not a specific glomerular disease
 Is a syndrome with a cluster of findings that
include:
 Marked increase in protein in urine (especially
albumin)
 Hypoalbuminemia
 Edema
 High serum cholesterol and LDL
 A condition of increased glomerular permeability
 Results in massive protein loss
 Often linked genetically or r/t
immune/inflammatory process
 Caused by chronic glomerulonephritis, diabetes
mellitus with glomerulosclerosis, amyloidosis,
lupus, multiple myeloma and renal vein
thrombosis
 Major manifestation is edema
 Hallmark is albuminuria exceeding 3.5g/day
Damaged glomerular
cap. membrane
Loss of plasma
protein (albumin)
Stimulates synthesis
of lipoproteins
hyperlipidemia
Damaged glomerular capillary
membrane
Loss of plasma proteins
hypoalbuminemia
Decreased oncotic pressure
Generalized edema>RAAS>sodium
retention>>>>edema
 Massive proteinuria
 Hypoalbuminemia
 Edema
 Lipiduria
 Hyperlipidemia
 Increased coagulation
 Renal insufficiency
 Renal biopsy to determine specific cause
 Steroids
 Immunosuppressive agents
 ACEIs can decrease proteinuria
 Cholesterol lowering agents
 Heparin to reduce coagulability
 Limit sodium intake
 Reversible clinical syndrome whereby there is
sudden and pronounced loss of kidney
function
 Occurs over hours to days
 Results in kidneys failure to excrete
nitrogenous wastes
Intrarenal actual parenchymal damage
 Prolonged renal ischemia from myoglobinuria
(rhabdo, trauma, burns), hemoglobinuria
(transfusion reaction, hemolytic anemia)
 Nephrotoxic agents like aminoglycosides,
radiopaque contrast, heavy metals, solvents,
NSAIDs, ACEIs, acute glomerulonephritis
Prerenal 60-70% of cases
 Volume depletion as seen in hemorrhage, renal
losses from diuretics, GI losses from vomiting,
diarrhea
 Impaired cardiac output 2ndary to MI, heart
failure, dysrhythmias, cardiogenic shock
 Vasodilation from sepsis, anaphylaxis,
antihypertensive meds
Postrenal
Urinary tract obstruction by calculi, tumors, BPH,
blood clots
1. Initiation occurs with the insult
2. Oliguria with urinary output less than
400ml/24h . rising potassium, BUN, Cr. Not
responsive to fluid challenges.
3. Diuresis period— gradual increase in urinary
output. Beginning recovery. Renal function
gradually improves
4. Recovery—may take 3-12 months. May have
permanent reduction in functioning of 1%-3%.
 Prerenal-hypotension, tachycardia, decreased
CO, decreased urinary output, lethargy
 intrarenal and postrenal—oliguria or anuria,
hypertension, tachycardia, SOB, orthopnea,
n/v, generalized edema and weight gain,
lethargy, confusion
 Nonoliguric form also exists. Phases are
similar.
 Elevated BUN and creatinine
 Sodium retention but may be deceptive due to
water retention
 Potassium increased
 Phosphorus increased
 Calcium decreased
 H&H decreased
 Sp. Gravity decreased and fixed
 Objectives : Restore normal
chemical balance and prevent complications
until restoration of renal function
 Identify and treat underlying cause
 Maintain fluid balance—wts, serial CVP
readings, BP, strict I&O
 May give Mannitol, Lasix or Edecrin
 May need temporary dialysis
 If prerenal, fluid challenges and diuretics to
enhance renal blood flow
 Oliguric renal failure, low dose dopamine.
Calcium channel blockers may be used to
prevent influx of calcium into kidney cells,
maintains cell integrity and increase GFR
 Hyperkalemia—closely monitor electrolytes
 Kayexalate/Sorbitol—may need Flexiseal
 IV dextrose, insulin and calcium may help shift
K+
 Cautious administration of any medication that
can be nephrotoxic
 Monitor ABGs and acid-base balance
 Monitor phosphate levels
 Azotemia and uremia are directly related to the
rate of protein breakdown
 Dietary proteins are individualized to each
patient. Is a catabolic state and if insufficient
intake, patient may lose up to 0.5-1 pounds
daily. Encourage high CHO. Protein needs for
non-dialysis patients need 0.6g/kg of body
weight
 Dialysis patients will need 1-1.5g/kg
 Fluid restriction=urine volume plus 500ml
 Monitor fluid and electrolyte balance
 Reduce metabolic demands
 Promote pulmonary function
 Prevent infection
 Provide skin care
 Provide support
 Progressive, irreversibe deterioration in renal
function
 Causation: #1 diabetes mellitus, hypertension,
glomerulonephritis, pyelonephritis, polycystic
kidney disease, vascular disorders, others
 Uremia---collection of nitrogenous wastes
normally excreted by the kidneys. S/S include:
HA, seizures, coma, dry skin, rapid pulse,
elevated BP, scanty urine, labored breathing
 Nephrons hypertrophy and work harder until
70-80% of renal function is lost
 Nephrons could only compensate by
decreasing water reabsorption thus:
 Hyposthenuria—loss of urine concentrating
ability occurs
 Polyuria—increased urine output
 Then isosthenuria—fixed osmolality
 Gradual decline in urinary output
1. GFR greater than or equal to 90mL/min/1.73
m2. Kidney damage w/normal or increased
GFR
2. GFR = 60-89, mild decrease in GFR
3. GFR = 30-59, moderate decrease in GFR
4. GFR = 15-29. severe decrease in GFR
5. GFR < 15. Kidney failure
 Every body system is affected
 CV—hypertension (RAAS), heart failure,
pulmonary edema, pericarditis, MI
 Pulm.—crackles, Kussmaul, pleuritic pain
 Derm—severe pruritus, uremic frost (urea
crystals)
 GI—n/v, anorexia, uremic fetor (ammonia
odor to breath), constipation or diarrhea
 Neurologic—LOC changes, confusion, seizures,
agitation, neuropathies, RLS
 Hematologic—anemia, thrombocytopenia
 Musculoskeletal—muscle cramps, renal
osteodystrophy, bone pain, bone fractures
 Metabolic changes—urea and creatinine,
sodium, potassium, acid-base, calcium and
phosphorus
 Calcium and phosphorus binders—Calcium
carbonate, calcium acetate
 Antihypertensives
 Antiseizure—valium or dilantin
 Erythropoietin
 Iron supplements
 Diet—CHO and fat, vitamins, restrict protein
Indications:
1. Uremia
2. Persistent hyperkalemia
3. Uncompensated metabolic acidosis
4. Fluid volume excess
5. Uremic encephalopathy
6. Remove toxic substances
 Based on principles of diffusion, osmosis and
ultrafiltration
 Diffusion—removal of toxins and wastes.
Move from blood to dialysate.
 Osmosis—excess water is removed. Goes from
area of higher solute concentration (blood) to
lower concentration (dialysate)
 Ultrafiltration—water moves from high
pressure area to lower pressure. Applied by
negative pressure, more efficient than just by
osmosis
 ASHD
 Disturbances of lipids worsened by dialysis
 Anemia and fatigue
 Gastric ulcers
 Renal osteodystrophy
 Sleep problems
 Hypotension
 Muscle cramps
 Dysrhythmias
 Dialysis equilibrium from cerebral fluid shifts
 Caused by rapid decrease in fluid volume and
blood urea nitrogen levels during HD
 Change in urea levels can cause cerebral edema
and increased ICP
 Neurologic complications include: HA,
vomiting, restlessness, decreased LOC,
seizures, coma or death
 Can be prevented by starting HD for short
periods and low blood flows
 Hemodialysis
 In ICUs where patient is too unstable to have
hemodialysis, can have CRRT
 Peritoneal dialysis
 More successful if done before dialysis
 HLA and ABO compatibility
 Donor kidney placed in iliac fossa
 Patient must be free from infection
 Similar care for patient post-op as any surgery
 Post-op—assess for s/s of rejection such as
oliguria, edema, fever, increasing blood
pressure, weight gain and swelling or
tenderness over transplanted area
 Monitor creatinine level, in those on
cyclosporine, may be the only s/s
 Monitor WBCs
 Monitor urinary output, may need
hemodialysis temporarily (2-3 weeks may
initially have ATN)
 Occurs in types 1 and 2
 Severity of diabetic renal disease is related to
extent, duration and effects of atherosclerosis,
htn and neuropathy.
 Microvascular complication of diabetes
 First manifestation is persistent albuminuria
 Diabetic patients are always considered to be at
risk for renal failure
 Avoid nephrotoxic agents and dehydration
 Stage 1—at time of diagnosis of diabetes.
Kidney size and GFR are increased. Blood
sugar control can reverse the changes.
 Stage 2, 2-3 years after diagnosis. Basement
membrane changes result in loss of filtration
surface area and scar formation. These changes
are called glomerulosclerosis.
 Stage 3, 7-15 years after diagnosis.
Microalbuminuria is present. GRF may be
normal or increased.
 Stage 4, albuminuria is detectable by dipstick.
GRF decreased. BP is increased. Retinopathy is
present.
 Stage V, GFR decreases at an average rate of
10ml/min./year
 Cystitis
 Ureterovesical reflux
 If bacteriuria, following should have cultures done:
 All men
 All children
 Patients with diabetics
 Those with recent instrumentation
 Those hospitalized or who live in long term care
 Pregnant women
 Sexually active
 Postmenopausal
 Obstruction
 Stones
 Diabetes mellitus
 Gender
 Age—anticholinergics, neuromuscular
conditions, hypoestrogenism
 Sexual activity
 Alkalotic urine
 Vesicoureteral reflux
 Most common organism is E. coli
 Other causative organisms are: S. saprophyticus,
K. pneumoniae, Proteus and Enterobacter
 Bactrim, Macrodantin, Cipro,Levaquin
 Fluids, avoid urinary irritants
 Hygiene
 Prevention
Acute pyelonephritis
 Will have fever, chills, leukocytosis, bacteriuria
and pyuria
 CVA tenderness
 US or CT to r/o any obstruction
 Urine C&S
 Tx:
 Hydration
 Antiemetics
 Two week course of antibiotics such as
Bactrim, Cipro, gentamycin w/or w/o
ampicillin, 3rd generation cephalosporin
 Pregnant women hospitalized for 2-3 days
 f/u culture in two weeks
 Stress incontinence—invol. loss of urine w/
activities that increase intraabdominal pressure
 Urge incontinence—unable to suppress signal
from bladder to brain
 Overflow incontinence-when bladder is distended,
will have small amount of incont.
 Functional incontinence as seen in Alzheimer’s
 Reflex incontinence as seen in SCI patients
 Mixed-stress and urge
 Neurogenic bladder—lesion of ns leads to urinary
incontinence
 May be caused by MS, SCI, HNP, spinal tumor,
spina bifida, diabetes
 Spastic—upper motor neuron lesion
 Flaccid—lower motor neuron lesion. Fills then
have overflow incontinence
 Assess by checking residuals, I&O, UA,
assessing sensory awareness
 Tx-urecholine, surgery, intermittent caths, S/P
caths
 Diuretics
 CNS depressants which affect LOC
 CVAs
 Parkinson’s
 Depression and altered self-esteem
 Inability to ambulate safely
 Assistance products cost prohibitive for patient
 UTI
 TCAs
 Anticholinergics—Sudafed, Detrol, Ditropan
 Estrogen in women
 Weight loss in obese
 Fluid management
 Transvaginal or transrectal electrical
stimulation
 Inflatable cuff
 Vaginal cone retention exercises
 Urinary catheterization
 Scheduled toileting
 Pelvic muscle exercises
 Presence of calculi in urinary tract
 Cause pain as they pass
 Nephrolithiasis is formation of stones in the
kidney
 Involves three conditions:
1. Slow urine flow resulting in supersaturation of
the urine with the particular element
2. Damage to the lining of the urinary tract
3. Decreased inhibitor substances in the urine
that would otherwise prevent supersaturation
and crystal aggregation
 Metabolic risk factors such as hyperuricemia,
hyperoxaluria or hypercalcemia
 High dietary calcium not contributive unless
metabolic or renal tubular defect exists
 Immobilization
 Urinary stasis, dehydration and urinary
retention mamy be causative
 Evaluate for bladder obstruction
 UA will reveal RBCs, odor, turbidity, WBCs
 MRI, KUB, CT
 Noncontrast helical CT has highest sensitivity
 IV urography will show obstruction
 Analgesia
 Avoid NSAIDs if to have lithotripsy (affect
platelets)
 Hydration
 Urine straining
 Lithotripsy (monitor ECG and sedate patient)
 Minimally invasive surgical procedures (MIS)
such as stenting, nephrolithotomy
 Antibiotics
 Thiazide diuretics for hypercalciuria
 Allopurinol and vitamin B6 for oxalate
containing stones
 Uric acid stone—allopurinol and alkalinizing
the urine. Sodium bicarbonate or potassium
citrate helpful.
 Cystine –captopril and
alphamercaptopropionylglycine w/ hydration
and alkalinazation of urine
 Urothelial
 Tx with BCG
 Radiation
 chemotherapy
 Ureterostomy
 Conduits—to intestine and stoma
 Sigmoidostomies-divert urine to large intestine
so no stoma
 Ileal reservoir—surgically created pouch

More Related Content

Similar to nur_4206--renal__updated_3-31-09.ppt

Dr tasnim acute & chronic renal failure
Dr tasnim acute & chronic renal failureDr tasnim acute & chronic renal failure
Dr tasnim acute & chronic renal failure
dr Tasnim
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
AdrianAddie De Jesus
 
Acute renal failure in icu
Acute renal failure in icuAcute renal failure in icu
Acute renal failure in icu
ZIKRULLAH MALLICK
 
CME: Acute Renal failure
CME: Acute Renal failureCME: Acute Renal failure
Renal function
Renal functionRenal function
Renal function
AFiFi Faridz
 
Renal support
Renal supportRenal support
Renal support
Mohammed Dabbour
 
34 chronic renal failure & dialysis
34 chronic renal failure & dialysis34 chronic renal failure & dialysis
34 chronic renal failure & dialysis
Dang Thanh Tuan
 
Renal Failure.pptx
Renal Failure.pptxRenal Failure.pptx
Renal Failure.pptx
DarshanS239776
 
renalfunctiontests01.ppt
renalfunctiontests01.pptrenalfunctiontests01.ppt
renalfunctiontests01.ppt
FarhanAbbas43
 
Chronic kidney disease and its management
Chronic kidney disease and its managementChronic kidney disease and its management
Chronic kidney disease and its management
Rajee Ravindran
 
AKI AND CKD
AKI AND CKDAKI AND CKD
AKI AND CKD
Eric General
 
AKI and CKD.ppt
AKI and CKD.pptAKI and CKD.ppt
AKI and CKD.ppt
RaphaelChitalima
 
ACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASE
ACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASEACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASE
ACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASE
JITENDRAKUMARDAS15
 
Guideline, management of acute kidney injury
Guideline, management of acute kidney injuryGuideline, management of acute kidney injury
Guideline, management of acute kidney injury
vita madmo
 
Nutritional Management of Renal Diseases
Nutritional Management of Renal DiseasesNutritional Management of Renal Diseases
Nutritional Management of Renal Diseases
Akansha Bhatnagar
 
renalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxrenalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptx
DebdattaMandal5
 
Renal function tests
Renal function testsRenal function tests
Renal function tests
velspharmd
 
Renal Revision
Renal RevisionRenal Revision
Renal Revision
meducationdotnet
 
Renal diseases 2.ppt
Renal diseases 2.pptRenal diseases 2.ppt
Renal diseases 2.ppt
Isatoubah3
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
internalmed
 

Similar to nur_4206--renal__updated_3-31-09.ppt (20)

Dr tasnim acute & chronic renal failure
Dr tasnim acute & chronic renal failureDr tasnim acute & chronic renal failure
Dr tasnim acute & chronic renal failure
 
Acute renal failure
Acute renal failureAcute renal failure
Acute renal failure
 
Acute renal failure in icu
Acute renal failure in icuAcute renal failure in icu
Acute renal failure in icu
 
CME: Acute Renal failure
CME: Acute Renal failureCME: Acute Renal failure
CME: Acute Renal failure
 
Renal function
Renal functionRenal function
Renal function
 
Renal support
Renal supportRenal support
Renal support
 
34 chronic renal failure & dialysis
34 chronic renal failure & dialysis34 chronic renal failure & dialysis
34 chronic renal failure & dialysis
 
Renal Failure.pptx
Renal Failure.pptxRenal Failure.pptx
Renal Failure.pptx
 
renalfunctiontests01.ppt
renalfunctiontests01.pptrenalfunctiontests01.ppt
renalfunctiontests01.ppt
 
Chronic kidney disease and its management
Chronic kidney disease and its managementChronic kidney disease and its management
Chronic kidney disease and its management
 
AKI AND CKD
AKI AND CKDAKI AND CKD
AKI AND CKD
 
AKI and CKD.ppt
AKI and CKD.pptAKI and CKD.ppt
AKI and CKD.ppt
 
ACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASE
ACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASEACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASE
ACUTE RENAL FAILURE OR ACUTE KIDNEY DISEASE
 
Guideline, management of acute kidney injury
Guideline, management of acute kidney injuryGuideline, management of acute kidney injury
Guideline, management of acute kidney injury
 
Nutritional Management of Renal Diseases
Nutritional Management of Renal DiseasesNutritional Management of Renal Diseases
Nutritional Management of Renal Diseases
 
renalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxrenalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptx
 
Renal function tests
Renal function testsRenal function tests
Renal function tests
 
Renal Revision
Renal RevisionRenal Revision
Renal Revision
 
Renal diseases 2.ppt
Renal diseases 2.pptRenal diseases 2.ppt
Renal diseases 2.ppt
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
 

More from AmirAhmedGeza

Perinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptxPerinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptx
AmirAhmedGeza
 
Chapter 1 Intro to Ms 2023.pptx
Chapter 1 Intro to Ms 2023.pptxChapter 1 Intro to Ms 2023.pptx
Chapter 1 Intro to Ms 2023.pptx
AmirAhmedGeza
 
ALTERATIONS IN OXYGENATION CMBC.pptx
ALTERATIONS IN OXYGENATION CMBC.pptxALTERATIONS IN OXYGENATION CMBC.pptx
ALTERATIONS IN OXYGENATION CMBC.pptx
AmirAhmedGeza
 
57 organization of NICU.ppt
57 organization of NICU.ppt57 organization of NICU.ppt
57 organization of NICU.ppt
AmirAhmedGeza
 
Skin disorder.pptx
Skin disorder.pptxSkin disorder.pptx
Skin disorder.pptx
AmirAhmedGeza
 
Found_39927be00-d1000.ppt
Found_39927be00-d1000.pptFound_39927be00-d1000.ppt
Found_39927be00-d1000.ppt
AmirAhmedGeza
 
14702401.ppt
14702401.ppt14702401.ppt
14702401.ppt
AmirAhmedGeza
 
Found_399085e00-c200.ppt
Found_399085e00-c200.pptFound_399085e00-c200.ppt
Found_399085e00-c200.ppt
AmirAhmedGeza
 
6 birth truama.pptx
6 birth truama.pptx6 birth truama.pptx
6 birth truama.pptx
AmirAhmedGeza
 
chapter 4 pedi ppt.pptx
chapter 4 pedi ppt.pptxchapter 4 pedi ppt.pptx
chapter 4 pedi ppt.pptx
AmirAhmedGeza
 
Neonatal sepsis.pptx
Neonatal sepsis.pptxNeonatal sepsis.pptx
Neonatal sepsis.pptx
AmirAhmedGeza
 
4647515.ppt
4647515.ppt4647515.ppt
4647515.ppt
AmirAhmedGeza
 
Normal Newborn & Common Neonatal problems.ppt
Normal Newborn & Common Neonatal problems.pptNormal Newborn & Common Neonatal problems.ppt
Normal Newborn & Common Neonatal problems.ppt
AmirAhmedGeza
 
managementofcommonneonataldisorders-211031062546.pdf
managementofcommonneonataldisorders-211031062546.pdfmanagementofcommonneonataldisorders-211031062546.pdf
managementofcommonneonataldisorders-211031062546.pdf
AmirAhmedGeza
 
Perinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptxPerinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptx
AmirAhmedGeza
 
chapter 3 new born care ppt.pptx
chapter 3 new born care ppt.pptxchapter 3 new born care ppt.pptx
chapter 3 new born care ppt.pptx
AmirAhmedGeza
 

More from AmirAhmedGeza (16)

Perinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptxPerinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptx
 
Chapter 1 Intro to Ms 2023.pptx
Chapter 1 Intro to Ms 2023.pptxChapter 1 Intro to Ms 2023.pptx
Chapter 1 Intro to Ms 2023.pptx
 
ALTERATIONS IN OXYGENATION CMBC.pptx
ALTERATIONS IN OXYGENATION CMBC.pptxALTERATIONS IN OXYGENATION CMBC.pptx
ALTERATIONS IN OXYGENATION CMBC.pptx
 
57 organization of NICU.ppt
57 organization of NICU.ppt57 organization of NICU.ppt
57 organization of NICU.ppt
 
Skin disorder.pptx
Skin disorder.pptxSkin disorder.pptx
Skin disorder.pptx
 
Found_39927be00-d1000.ppt
Found_39927be00-d1000.pptFound_39927be00-d1000.ppt
Found_39927be00-d1000.ppt
 
14702401.ppt
14702401.ppt14702401.ppt
14702401.ppt
 
Found_399085e00-c200.ppt
Found_399085e00-c200.pptFound_399085e00-c200.ppt
Found_399085e00-c200.ppt
 
6 birth truama.pptx
6 birth truama.pptx6 birth truama.pptx
6 birth truama.pptx
 
chapter 4 pedi ppt.pptx
chapter 4 pedi ppt.pptxchapter 4 pedi ppt.pptx
chapter 4 pedi ppt.pptx
 
Neonatal sepsis.pptx
Neonatal sepsis.pptxNeonatal sepsis.pptx
Neonatal sepsis.pptx
 
4647515.ppt
4647515.ppt4647515.ppt
4647515.ppt
 
Normal Newborn & Common Neonatal problems.ppt
Normal Newborn & Common Neonatal problems.pptNormal Newborn & Common Neonatal problems.ppt
Normal Newborn & Common Neonatal problems.ppt
 
managementofcommonneonataldisorders-211031062546.pdf
managementofcommonneonataldisorders-211031062546.pdfmanagementofcommonneonataldisorders-211031062546.pdf
managementofcommonneonataldisorders-211031062546.pdf
 
Perinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptxPerinatal asphyxia.lecture.pptx
Perinatal asphyxia.lecture.pptx
 
chapter 3 new born care ppt.pptx
chapter 3 new born care ppt.pptxchapter 3 new born care ppt.pptx
chapter 3 new born care ppt.pptx
 

Recently uploaded

Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 

Recently uploaded (20)

Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 

nur_4206--renal__updated_3-31-09.ppt

  • 2.  Regulation of water excretion  Regulation of electrolyte function  Regulation of acid-base balance—retain HCO3- and excrete acid in urine  Regulation of blood pressure--RAAS  Regulation of RBCs  Vitamin D synthesis
  • 3.  Secretion of prostaglandin E and prostacyclin which cause vasodilation, important in maintaining renal blood flow  Excretion of waste products-body’s main excretory organ. Urea, creatinine, phosphates, uric acid and sulfates. Drug metabolites.
  • 4. Stimuli for Renin Excretion Angiotensinogen in liver Renin release Angiotensin I Converting enzyme in lungs Angiotensin II Renal autoregulation Increased BP, increased circulating volume
  • 5.  Renin—raises BP  Bradykinins—increase blood flow and vascular permeability  Erythropoietin  ADH  Aldosterone—promotes sodium reabsorption and potassium excretion  Natriuretic hormones—released from the cardiac atria and brain.
  • 6. 1. Hypertension 2. Diabetes mellitus 3. Immobilization 4. Parkinson’s disease 5. SLE 6. Gout 7. Sickle cell anemia, multiple myeloma 8. BPH 9. Pregnancy 10. SCI
  • 7.  GFR decreases following 40 years with a yearly decline of about 1 mL/min  Renal reserve declines  Multiple medications can result in toxic metabolites  Diminished osmotic stimulation of thirst  Incomplete emptying of bladder  Urinary incontinence
  • 8.
  • 9.  Sp. Gravity—1.005-1.020  Microscopic examination for protein, RBCs, ketones, glycosuria, presence of bacteria, general appearance and odor  Leukocyte esterase—enzyme found in WBCs  Nitrites –bacteria convert nitrates to nitrites  Osmolality—accurate measurement of the kidney’s ability to concentrate urine. Normal range is 500-1200 mOsm/kg.  Culture important in ‘Id’ing pathogen
  • 10.  Albuminuria—albumin in urine not measurable by dipstick  Normal values in freshly voided sample should range between 2.0-20 for men and 2.8-28 for women. Higher levels indicate microalbuminuria.  Can also be determined by 24h specimen
  • 11.  Urine osmolality—indication of concentrating ability, changes seen early in disease processes  Creatinine clearance—tests clearance of creatinine in one min. Reflects GFR.  Serum creatinine—measures effectiveness of renal function. 0.6 to 1.2 mg/dL  Urea nitrogen—also indicator of renal function. 7-18 mg/dL. Measures renal excretion of urea nitirogen, a byproduct of protein metabolism. Is not always elevated with kidney disease. Not best indicator of renal function.
  • 12.  Liver must function properly to produce urea nitrogen. BUN levels indicate the extent of renal clearance of this nitrogenous waste product.  May see elevation of BUN with bleeding into tissues or from rapid cell destruction from infection/steroids
  • 13.  Ratio of BUN to creatinine distinguishes between renal and non-renal factors causing elevations  Dehydration can affect the BUN  When blood volume is down, or BP is low, BUN level rises more rapidly than creatinine level.
  • 14.  Volume of fluid filtered from renal glomerular capillaries into Bowman’s capsule per unit of time  Generally expressed in ml/minute  Normal GFR generally is 125mL/minute
  • 15.  Cockcraft-Gault formula  Modification of Diet in Renal Disease Study Group formula (MDRD)  Schwartz formula  Starling equation
  • 16.
  • 17.  No common pathologic condition, other than renal disease, increases the serum creatinine level  Serum creatinine does not increase until at least 50% of renal function is lost
  • 18.  Is a calculated measure of glomerular filtration rate. Is best indicator of overall kidney function.  Based on 24 hour urine collection  Midway will obtain serum creatinine. Serum creatinine levels vary with age, gender and body muscle mass  Calculate: (Volume of urine X urine creatinine) Divided by serume creatinine
  • 19.  KUB  Ultrasonography  CT  MRI  Nuclear scans  IV urography—IVP. NPO before. Bowel prep. Nephrotoxic agent. Metformin.  VCUG
  • 20.  Cystoscopy  Ureteral brush biopsy  Kidney biopsy  Urodynamic tests—cystometrogram. Measures detrusor muscle function.
  • 21.  Antigen-antibody complexes form in blood and become trapped in glomerular capillaries  Induce an inflammatory response  Manifested by proteinuria, hematuria, decreased GFR and alteration in excretion of sodium  Acute and chronic glomerulonephritis  Nephrotic syndrome
  • 22. Antigen (group A strep) Antigen-antibody product Deposition of antigen-antibody complex in glomerulus Increased production of epithelial cells lining the glomerulus Leukocyte infultration of the glomerulus Thickening of the glomerular filtration membrane Scarring and loss of glomerular filtration membrane Decreased GFR
  • 23.  Staph, klebsiella, CMV, mono, hep B, mycoplasma, group A beta-hemolytic strep
  • 24.  Hematuria  Edema  Azotemia-accumulation of nitrogenous wastes  Urine appearance may be cola colored  Hypertension  Hypoalbuminemia  Hyperlipidemia  Rising BUN and creatinine
  • 25.  Hypertensive encephalopathy  Heart failure  Rapid decline in renal function can occur to ESRD
  • 26.  Treat s/s such as elevated BP  Check GFR by 24h urine for creatinine clearance  ANA  Treat streptococcal infection with antibiotics, preferably PCN  Corticosteroids  Immunosuppressants  Limit dietary protein, increase CHO  Restrict sodium  May progress to chronic glomerulonephritis, will treat as in CKD
  • 27.  Is not a specific glomerular disease  Is a syndrome with a cluster of findings that include:  Marked increase in protein in urine (especially albumin)  Hypoalbuminemia  Edema  High serum cholesterol and LDL
  • 28.  A condition of increased glomerular permeability  Results in massive protein loss  Often linked genetically or r/t immune/inflammatory process  Caused by chronic glomerulonephritis, diabetes mellitus with glomerulosclerosis, amyloidosis, lupus, multiple myeloma and renal vein thrombosis  Major manifestation is edema  Hallmark is albuminuria exceeding 3.5g/day
  • 29. Damaged glomerular cap. membrane Loss of plasma protein (albumin) Stimulates synthesis of lipoproteins hyperlipidemia
  • 30. Damaged glomerular capillary membrane Loss of plasma proteins hypoalbuminemia Decreased oncotic pressure Generalized edema>RAAS>sodium retention>>>>edema
  • 31.  Massive proteinuria  Hypoalbuminemia  Edema  Lipiduria  Hyperlipidemia  Increased coagulation  Renal insufficiency
  • 32.  Renal biopsy to determine specific cause  Steroids  Immunosuppressive agents  ACEIs can decrease proteinuria  Cholesterol lowering agents  Heparin to reduce coagulability  Limit sodium intake
  • 33.  Reversible clinical syndrome whereby there is sudden and pronounced loss of kidney function  Occurs over hours to days  Results in kidneys failure to excrete nitrogenous wastes
  • 34. Intrarenal actual parenchymal damage  Prolonged renal ischemia from myoglobinuria (rhabdo, trauma, burns), hemoglobinuria (transfusion reaction, hemolytic anemia)  Nephrotoxic agents like aminoglycosides, radiopaque contrast, heavy metals, solvents, NSAIDs, ACEIs, acute glomerulonephritis
  • 35. Prerenal 60-70% of cases  Volume depletion as seen in hemorrhage, renal losses from diuretics, GI losses from vomiting, diarrhea  Impaired cardiac output 2ndary to MI, heart failure, dysrhythmias, cardiogenic shock  Vasodilation from sepsis, anaphylaxis, antihypertensive meds
  • 36. Postrenal Urinary tract obstruction by calculi, tumors, BPH, blood clots
  • 37. 1. Initiation occurs with the insult 2. Oliguria with urinary output less than 400ml/24h . rising potassium, BUN, Cr. Not responsive to fluid challenges. 3. Diuresis period— gradual increase in urinary output. Beginning recovery. Renal function gradually improves 4. Recovery—may take 3-12 months. May have permanent reduction in functioning of 1%-3%.
  • 38.  Prerenal-hypotension, tachycardia, decreased CO, decreased urinary output, lethargy  intrarenal and postrenal—oliguria or anuria, hypertension, tachycardia, SOB, orthopnea, n/v, generalized edema and weight gain, lethargy, confusion
  • 39.  Nonoliguric form also exists. Phases are similar.
  • 40.  Elevated BUN and creatinine  Sodium retention but may be deceptive due to water retention  Potassium increased  Phosphorus increased  Calcium decreased  H&H decreased  Sp. Gravity decreased and fixed
  • 41.  Objectives : Restore normal chemical balance and prevent complications until restoration of renal function  Identify and treat underlying cause  Maintain fluid balance—wts, serial CVP readings, BP, strict I&O  May give Mannitol, Lasix or Edecrin  May need temporary dialysis
  • 42.  If prerenal, fluid challenges and diuretics to enhance renal blood flow  Oliguric renal failure, low dose dopamine. Calcium channel blockers may be used to prevent influx of calcium into kidney cells, maintains cell integrity and increase GFR
  • 43.  Hyperkalemia—closely monitor electrolytes  Kayexalate/Sorbitol—may need Flexiseal  IV dextrose, insulin and calcium may help shift K+  Cautious administration of any medication that can be nephrotoxic  Monitor ABGs and acid-base balance  Monitor phosphate levels
  • 44.  Azotemia and uremia are directly related to the rate of protein breakdown  Dietary proteins are individualized to each patient. Is a catabolic state and if insufficient intake, patient may lose up to 0.5-1 pounds daily. Encourage high CHO. Protein needs for non-dialysis patients need 0.6g/kg of body weight  Dialysis patients will need 1-1.5g/kg  Fluid restriction=urine volume plus 500ml
  • 45.  Monitor fluid and electrolyte balance  Reduce metabolic demands  Promote pulmonary function  Prevent infection  Provide skin care  Provide support
  • 46.  Progressive, irreversibe deterioration in renal function  Causation: #1 diabetes mellitus, hypertension, glomerulonephritis, pyelonephritis, polycystic kidney disease, vascular disorders, others  Uremia---collection of nitrogenous wastes normally excreted by the kidneys. S/S include: HA, seizures, coma, dry skin, rapid pulse, elevated BP, scanty urine, labored breathing
  • 47.  Nephrons hypertrophy and work harder until 70-80% of renal function is lost  Nephrons could only compensate by decreasing water reabsorption thus:  Hyposthenuria—loss of urine concentrating ability occurs  Polyuria—increased urine output  Then isosthenuria—fixed osmolality  Gradual decline in urinary output
  • 48. 1. GFR greater than or equal to 90mL/min/1.73 m2. Kidney damage w/normal or increased GFR 2. GFR = 60-89, mild decrease in GFR 3. GFR = 30-59, moderate decrease in GFR 4. GFR = 15-29. severe decrease in GFR 5. GFR < 15. Kidney failure
  • 49.  Every body system is affected  CV—hypertension (RAAS), heart failure, pulmonary edema, pericarditis, MI  Pulm.—crackles, Kussmaul, pleuritic pain  Derm—severe pruritus, uremic frost (urea crystals)  GI—n/v, anorexia, uremic fetor (ammonia odor to breath), constipation or diarrhea  Neurologic—LOC changes, confusion, seizures, agitation, neuropathies, RLS
  • 50.  Hematologic—anemia, thrombocytopenia  Musculoskeletal—muscle cramps, renal osteodystrophy, bone pain, bone fractures  Metabolic changes—urea and creatinine, sodium, potassium, acid-base, calcium and phosphorus
  • 51.  Calcium and phosphorus binders—Calcium carbonate, calcium acetate  Antihypertensives  Antiseizure—valium or dilantin  Erythropoietin  Iron supplements  Diet—CHO and fat, vitamins, restrict protein
  • 52. Indications: 1. Uremia 2. Persistent hyperkalemia 3. Uncompensated metabolic acidosis 4. Fluid volume excess 5. Uremic encephalopathy 6. Remove toxic substances
  • 53.  Based on principles of diffusion, osmosis and ultrafiltration  Diffusion—removal of toxins and wastes. Move from blood to dialysate.  Osmosis—excess water is removed. Goes from area of higher solute concentration (blood) to lower concentration (dialysate)  Ultrafiltration—water moves from high pressure area to lower pressure. Applied by negative pressure, more efficient than just by osmosis
  • 54.  ASHD  Disturbances of lipids worsened by dialysis  Anemia and fatigue  Gastric ulcers  Renal osteodystrophy  Sleep problems  Hypotension  Muscle cramps  Dysrhythmias  Dialysis equilibrium from cerebral fluid shifts
  • 55.  Caused by rapid decrease in fluid volume and blood urea nitrogen levels during HD  Change in urea levels can cause cerebral edema and increased ICP  Neurologic complications include: HA, vomiting, restlessness, decreased LOC, seizures, coma or death  Can be prevented by starting HD for short periods and low blood flows
  • 56.  Hemodialysis  In ICUs where patient is too unstable to have hemodialysis, can have CRRT  Peritoneal dialysis
  • 57.  More successful if done before dialysis  HLA and ABO compatibility  Donor kidney placed in iliac fossa  Patient must be free from infection  Similar care for patient post-op as any surgery
  • 58.  Post-op—assess for s/s of rejection such as oliguria, edema, fever, increasing blood pressure, weight gain and swelling or tenderness over transplanted area  Monitor creatinine level, in those on cyclosporine, may be the only s/s  Monitor WBCs  Monitor urinary output, may need hemodialysis temporarily (2-3 weeks may initially have ATN)
  • 59.  Occurs in types 1 and 2  Severity of diabetic renal disease is related to extent, duration and effects of atherosclerosis, htn and neuropathy.
  • 60.  Microvascular complication of diabetes  First manifestation is persistent albuminuria  Diabetic patients are always considered to be at risk for renal failure  Avoid nephrotoxic agents and dehydration
  • 61.  Stage 1—at time of diagnosis of diabetes. Kidney size and GFR are increased. Blood sugar control can reverse the changes.  Stage 2, 2-3 years after diagnosis. Basement membrane changes result in loss of filtration surface area and scar formation. These changes are called glomerulosclerosis.
  • 62.  Stage 3, 7-15 years after diagnosis. Microalbuminuria is present. GRF may be normal or increased.  Stage 4, albuminuria is detectable by dipstick. GRF decreased. BP is increased. Retinopathy is present.  Stage V, GFR decreases at an average rate of 10ml/min./year
  • 64.  If bacteriuria, following should have cultures done:  All men  All children  Patients with diabetics  Those with recent instrumentation  Those hospitalized or who live in long term care  Pregnant women  Sexually active  Postmenopausal
  • 65.  Obstruction  Stones  Diabetes mellitus  Gender  Age—anticholinergics, neuromuscular conditions, hypoestrogenism  Sexual activity  Alkalotic urine  Vesicoureteral reflux
  • 66.  Most common organism is E. coli  Other causative organisms are: S. saprophyticus, K. pneumoniae, Proteus and Enterobacter
  • 67.  Bactrim, Macrodantin, Cipro,Levaquin  Fluids, avoid urinary irritants  Hygiene  Prevention
  • 68. Acute pyelonephritis  Will have fever, chills, leukocytosis, bacteriuria and pyuria  CVA tenderness  US or CT to r/o any obstruction  Urine C&S
  • 69.  Tx:  Hydration  Antiemetics  Two week course of antibiotics such as Bactrim, Cipro, gentamycin w/or w/o ampicillin, 3rd generation cephalosporin  Pregnant women hospitalized for 2-3 days  f/u culture in two weeks
  • 70.  Stress incontinence—invol. loss of urine w/ activities that increase intraabdominal pressure  Urge incontinence—unable to suppress signal from bladder to brain  Overflow incontinence-when bladder is distended, will have small amount of incont.  Functional incontinence as seen in Alzheimer’s  Reflex incontinence as seen in SCI patients  Mixed-stress and urge  Neurogenic bladder—lesion of ns leads to urinary incontinence
  • 71.  May be caused by MS, SCI, HNP, spinal tumor, spina bifida, diabetes  Spastic—upper motor neuron lesion  Flaccid—lower motor neuron lesion. Fills then have overflow incontinence  Assess by checking residuals, I&O, UA, assessing sensory awareness  Tx-urecholine, surgery, intermittent caths, S/P caths
  • 72.  Diuretics  CNS depressants which affect LOC  CVAs  Parkinson’s  Depression and altered self-esteem  Inability to ambulate safely  Assistance products cost prohibitive for patient  UTI
  • 73.  TCAs  Anticholinergics—Sudafed, Detrol, Ditropan  Estrogen in women
  • 74.  Weight loss in obese  Fluid management  Transvaginal or transrectal electrical stimulation  Inflatable cuff  Vaginal cone retention exercises  Urinary catheterization  Scheduled toileting  Pelvic muscle exercises
  • 75.  Presence of calculi in urinary tract  Cause pain as they pass  Nephrolithiasis is formation of stones in the kidney
  • 76.  Involves three conditions: 1. Slow urine flow resulting in supersaturation of the urine with the particular element 2. Damage to the lining of the urinary tract 3. Decreased inhibitor substances in the urine that would otherwise prevent supersaturation and crystal aggregation
  • 77.  Metabolic risk factors such as hyperuricemia, hyperoxaluria or hypercalcemia  High dietary calcium not contributive unless metabolic or renal tubular defect exists  Immobilization  Urinary stasis, dehydration and urinary retention mamy be causative
  • 78.  Evaluate for bladder obstruction  UA will reveal RBCs, odor, turbidity, WBCs  MRI, KUB, CT  Noncontrast helical CT has highest sensitivity  IV urography will show obstruction
  • 79.  Analgesia  Avoid NSAIDs if to have lithotripsy (affect platelets)  Hydration  Urine straining  Lithotripsy (monitor ECG and sedate patient)  Minimally invasive surgical procedures (MIS) such as stenting, nephrolithotomy
  • 80.  Antibiotics  Thiazide diuretics for hypercalciuria  Allopurinol and vitamin B6 for oxalate containing stones  Uric acid stone—allopurinol and alkalinizing the urine. Sodium bicarbonate or potassium citrate helpful.  Cystine –captopril and alphamercaptopropionylglycine w/ hydration and alkalinazation of urine
  • 81.  Urothelial  Tx with BCG  Radiation  chemotherapy
  • 82.  Ureterostomy  Conduits—to intestine and stoma  Sigmoidostomies-divert urine to large intestine so no stoma  Ileal reservoir—surgically created pouch

Editor's Notes

  1. Vasa recta are specialized vessels that monitor BP. Renin is then excreted=angiotensinogen, angiotgensin I and the II (most powerful vasoconstrictor known) Aldosterone will be excreted in response to pituitary in response to poor perfusion or increasing osmolality Renal clearance—ability of kidneys to clear solutes from plasma Creatinine is waste product of skeletal muscle that is filtered at glomerulus and excreted in urine Erythropoietin in response to low oxygen tension Kidneys final conversion of inactive Vitamin D to active form 1,25 dihydroxycholecalciferol
  2. Prostaglandin important in vasodilatory action
  3. Renin excretion prompted by decreased renal perfusion and/or decreased salt delivery to kidney tubules, e.g. hemorrhage, heart failure, loop diuretics Increased BP—vasoconstriction, increased myocardial contractility, prostaglandin release Increased circulating volume—aldosterone release, sodium and water reabsorption, potassium excretion, ADH release
  4. Renin—2ndary to angiotensin and aldosterone Bradykinins—increase blood flow and vascular permeability ADH—fr. Post. Pituitary. Maximizes reabsorption of water in the kidney and produces a concentrated urine. Aldosterone—fr. Adrenal cortex. Promotes sodium reabsorption and potassium secretion in distal collecting tubules. Water and chloride follow sodium. Natriuretic hormones—cause tubular secretion of sodium. Release from cardiac atria and brain.
  5. CRF 2. CRF 3. lithiasis 4. incontinence 5. renal failure, nephritis 6. lithiasis 7. Renal failure 8. obstruction 9. proteinuria, frequent voiding 10. neurogenic bladder, UTIs, incontinence
  6. Microalbuminuria not measurable by dipstick Leukocyte esterase—enzyme found in some WBCs. Nitrites—converted from nitrates if enough bacteria present.
  7. creatinine is end product of muscle energy metabolism. Usually remains constant.